Janusz Michalewski, Slawomir Cisiecki, Krzysztof Dziegielewski, Zbigniew Pikulski, Dominik Odrobina, Jerzy Nawrocki (Lodz, Poland)


To describe and analyze morphological changes in the retina of patients treated on demand with intravitreal bevacizumab for more than 18 months.


Patients with exudative AMD were treated when activity of CNV in Spectral domain OCT (SOCT) was detected. Complete ophthalmic examinations, ETDRS, SOCT were performed every month. All follow up Spectral domain OCT scans of 33 patients treated with intravitreal bevacizumab were analyzed. Morphological data were correlated with VA.

Effectiveness / Safety:

In all patients progressive subretinal fibrosis and degeneration of outer retinal layers was detected despite successful treatment.

Take home message:

Long-term data suggest that chronic treatment on demand with intravitreal bevacizumab leads to progressive retinal damage.